Retractable Technologies makes and sells safety syringes and needles for the healthcare industry, with its products distinguished by a needle retraction mechanism that protects healthcare workers from needlestick injuries and reduces cross-contamination risk. The two core product lines are VanishPoint syringes, which feature passive auto-retraction that activates while the needle is still in the patient, and EasyPoint needles, retractable needles compatible with standard Luer-fitting syringes. The 1mL VanishPoint syringe is designed as a low dead space syringe, reducing medication waste and making it well-suited for vaccine administration. Retractable Technologies sells to healthcare providers through distributors, though purchasing decisions are largely controlled by group purchasing organizations, making GPO relationships central to the sales process. The company manufactures at its Little Elm, Texas facility and also sources from Chinese manufacturers, though current 120% tariffs on Chinese syringes and needles are pressuring costs, and the company is shifting more production to its domestic facility — supported by an $81M expansion funded through a U.S. Department of Defense agreement with BARDA. Revenue is primarily driven by unit volume and pricing, with a meaningful portion tied to vaccine administration demand, making the business sensitive to vaccination trends and public health campaigns. A notable cost of doing business is a 5% royalty on gross sales of covered products paid to founder and CEO Thomas Shaw, who holds joint ownership of key patents under an exclusive license agreement in place since 1995. Core VanishPoint patents expire between 2028 and 2032, and the company has filed for patents on updated designs to extend protection.